Published in J Mammary Gland Biol Neoplasia on January 01, 2003
Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res (2008) 2.22
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene (2007) 1.24
Synthesis and cancer chemopreventive activity of zapotin, a natural product from Casimiroa edulis. J Med Chem (2007) 0.81
Predictors of willingness to participate in window-of-opportunity breast trials. Clin Med Res (2013) 0.76
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 4.36
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev (2009) 2.66
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst (2003) 2.25
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol (2012) 2.22
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation (2005) 2.01
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst (2007) 1.97
Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol (2009) 1.85
Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat (2007) 1.82
Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol (2007) 1.60
Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol (2012) 1.57
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation (2002) 1.57
Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol (2011) 1.56
Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res (2004) 1.50
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol (2006) 1.47
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol (2011) 1.39
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet (2012) 1.23
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Metformin and breast cancer risk. J Clin Oncol (2013) 1.15
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat (2007) 1.12
Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer (2004) 1.11
Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila) (2010) 1.06
Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. Breast Cancer Res Treat (2008) 1.05
Lifestyle and breast cancer recurrences: the DIANA-5 trial. Tumori (2012) 1.04
Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol (2008) 1.01
Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res (2008) 1.01
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) (2011) 0.99
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res (2014) 0.99
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat (2014) 0.97
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat (2014) 0.95
Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol (2009) 0.94
Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Res Treat (2004) 0.93
A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res (2004) 0.92
Vitamin D supplementation and cancer: review of randomized controlled trials. Anticancer Agents Med Chem (2013) 0.92
Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol (2006) 0.91
Vitamin D receptor polymorphisms and cancer. Adv Exp Med Biol (2014) 0.90
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2014) 0.89
A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Cancer Epidemiol Biomarkers Prev (2006) 0.89
Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? J Biomed Biotechnol (2012) 0.88
Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res (2012) 0.87
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet (2011) 0.87
Potential use of vaccines in the primary prevention of breast cancer in high-risk patients. Breast Care (Basel) (2012) 0.87
Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. Cancer (2002) 0.86
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat (2012) 0.85
Fenretinide and risk reduction of second breast cancer. Nat Clin Pract Oncol (2007) 0.84
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clin Cancer Res (2010) 0.84
E-cadherin germline mutation carriers: clinical management and genetic implications. Cancer Metastasis Rev (2014) 0.84
Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology. Contemp Clin Trials (2010) 0.83
Biomarkers for risk assessment and prevention of breast cancer. Curr Cancer Drug Targets (2009) 0.82
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res (2013) 0.82